Goldman Sachs
AARD

Goldman Sachs’s Aardvark Therapeutics AARD Stock Holding History

Goldman Sachs’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.2K Sell
19,404
-33,945
-64% -$352K ﹤0.01% 6251
2025
Q4 		$700K Buy
53,349
+34,422
+182% +$430K ﹤0.01% 5384
2025
Q3 		$252K Buy
18,927
+332
+2% +$3.74K ﹤0.01% 5850
2025
Q2 		$251K Sell
18,595
-1,716
-8% -$17.7K ﹤0.01% 5544
2025
Q1 		$153K Buy
+20,311
New +$228K ﹤0.01% 5698

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs's AARD Position: Q1 2026 in Review

Goldman Sachs reduced its Aardvark Therapeutics (AARD) stake by 64% in Q1 2026, selling an estimated $352K and leaving 19,404 shares worth $73.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6251.

Goldman Sachs first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $700K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Goldman Sachs held 19,404 shares of Aardvark Therapeutics worth $73.2K as of Q1 2026.
  • Goldman Sachs sold 33,945 Aardvark Therapeutics shares in Q1 2026, an estimated $352K.
  • Aardvark Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6251 holding.
  • Goldman Sachs first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Goldman Sachs's Aardvark Therapeutics position peaked at $700K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.